Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

Sanofi and AstraZeneca signed SPICs with the Russian Ministry

On October 16, Sanofi and AstraZeneca signed special investment contracts (SPICs) with the Russian Ministry of Industry and Trade and Russian regions

AstraZeneca obtains approval of inter-agency commission to conclude SPIC

AstraZeneca announced that it obtained the approval of inter-agency commission for the conclusion of a special-purpose investment contract

AstraZeneca starts manufacturing drug targeting cancer cells in Kaluga

astrazeneca kaluga
AstraZeneca, an international biopharmaceutical company, launched a new high-tech manufacturing process at its plant in Vorsino industrial park of Kaluga region

AstraZeneca and Takeda will develop Parkinson’s disease drug

Parkinsons disease
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341

Ethris and AstraZeneca will collaborate on mRNA therapies

Ethris GmbH, a leader in mRNA-based therapeutics, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune

FDA aknowledged AstraZeneca’s cancer drug as Breakthrough Therapy Designation

fda office
AstraZeneca and MedImmune yesterday announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for Imfinzi (durvalumab)

AstraZeneca and Merck started oncology collaboration

AstraZeneca and Merck & Co., Inc., known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration

AstraZeneca invests $100 million in its hi-tech Australian facility

AstraZeneca has announced a $100 million expansion of its Sydney manufacturing facility aimed at boosting its exports to the growing Chinese market.

Chi-Med and AstraZeneca start phase III trial of kidney cancer drug

Chi-Med and AstraZeneca announced the initiation of a global pivotal Phase III, open-label, randomized multi-center registration study

Grünenthal buys global rights for AstraZeneca migraine drug

The Grünenthal Group today announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig

AstraZeneca’s breast cancer drug showed positive results in clinical trial

AstraZeneca presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival

AstraZeneca sold rights for Seloken drug to Recordati

AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken.

Skolkovo Foundation and AstraZeneca sign a strategic partnership agreement

Skolkovo Foundation and AstraZeneca, an international biopharmaceutical company, have agreed on a strategic partnership in the area of research and educational activities in Russia. The parties int...

AstraZeneca reported successful clinical trial of lung cancer drug

AstraZeneca and MedImmune, its global biologics research and development arm, have announced positive results for a trial of its lung cancer drug Imfinzi (durvalumab). The phase III PACIFIC tri...

AstraZeneca will develop respiratory drug with Pieris Pharmaceuticals

Pieris announced a strategic collaboration in respiratory diseases with AstraZeneca to develop novel inhaled drugs that leverage Pieris' Anticalin platform, including its lead preclinical drug candida...

AstraZeneca opened strategic R&D centre in Cambridge, UK

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the ‘topping out’ of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart ...